found Documents: 426

Announcements & Press Releases, Oncology / Immunology, Press Releases | 6 Mar 2018

Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China

1 item

London: Tuesday, March 6, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase Ib/II proof-of-concept study of epitinib in glioblastoma patients with epidermal growth factor receptor (“EGFR”) gene amplifi

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 13 Feb 2018

Chi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer

1 item

London: Tuesday, February 13, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has completed patient enrollment of FALUCA, its Phase III pivotal trial of fruquintinib in advanced, third-line, non-small cell lung cancer (“NSC

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 15 Dec 2017

Chi-Med Initiates Fruquintinib U.S. Clinical Trials

1 item

London: Friday, December 15, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated the United States Phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly selective and potent oral inhibitor of vas

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 31 Oct 2017

Chi-Med Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer

1 item

London: Tuesday, October 31, 2017: Hutchison China MediTech Limited (“Chi‑Med”) (AIM/Nasdaq: HCM) has initiated FRUTIGA, a pivotal Phase III clinical trial of fruquintinib in combination with paclitaxel (Taxol®) for the treatment in advanced g

Download Press Release (PDF)

Announcements & Press Releases, Group | 30 Oct 2017

Chi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select Market

1 item

London: Monday, October 30, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today the closing of its underwritten public offering of American Depositary Shares ("ADSs") on the Nasdaq Global Select Market, previously

Download Announcement (PDF)

Announcements & Press Releases, Group | 27 Oct 2017

Chi-Med Announces the Full Exercise of Underwriters' Over-allotment Option

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Friday, October 27, 2017: Hutchison China MediTech L

Download Announcement (PDF)

Announcements & Press Releases, Group | 26 Oct 2017

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market (RNS)

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Wednesday, October 25, 2017: Hutchison China MediTec

Download Announcement (PDF)

Group, Press Releases | 26 Oct 2017

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market

1 item

London: Wednesday, October 25, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today the pricing of the underwritten public offering previously announced by Chi-Med on October 24, 2017. Chi-Med will issue and sell 9

Download Press Release (PDF)

Announcements & Press Releases, Group | 25 Oct 2017

Chi-Med Announces Proposed Offering of ADSs (RNS)

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Tuesday, October 24, 2017: Hutchison China MediTech

Download Full Announcement (PDF, 87 pages including Appendix)

Group, Press Releases | 24 Oct 2017

Chi-Med Announces Proposed Offering of ADSs

1 item

London: Tuesday, October 24, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today that it intends to offer, subject to market and other conditions, US$262.0 million of American Depositary Shares (“ADSs”), each

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 17 Oct 2017

Chi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification

1 item

– Data for savolitinib in combination with Tagrisso® or Iressa® presented at World Conference on Lung Cancer – – New data give insights into disease progression and potential next-generation treatment strategies in patients with EGFR-muta

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 16 Oct 2017

Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer

1 item

Press Release – Fruquintinib in combination with Iressa® (gefitinib) shows promising efficacy and an acceptable safety profile – – Further validation of strong potential for use of fruquintinib in combination with other cancer therapies du

Downoad Press Release (PDF)

Announcements & Press Releases, Group, Press Releases | 12 Oct 2017

Chi-Med Appoints Professor Tony Mok to Board of Directors

1 item

Appointment of Director London: Thursday, October 12, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Professor Mok, Shu Kam Tony has been appointed as Independent Non-Executive Director and member of t

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Sep 2017

Chi-Med Highlights Oral Presentations at CSCO Annual Meeting

1 item

Press Release – Three oral presentations given at CSCO for fruquintinib, savolitinib and theliatinib – – Plenary keynote presentation for FRESCO Phase III trial details analysis showing consistent survival benefit in all key subgroups

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Sep 2017

Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting

1 item

Press Release – Data to show potential of savolitinib to treat EGFR-TKI resistance in both Iressa® and Tagrisso® refractory patients with MET amplification – – Results to further validate Chi-Med’s scientific strategy of designing highly

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Aug 2017

Chi‑Med Initiates a Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL‑689 in Lymphoma Patients in China

1 item

Press Release London: Tuesday, August 29, 2017: Hutchison China MediTech Limited (“Chi‑Med”) (AIM/Nasdaq: HCM) has initiated a Phase I clinical trial of HMPL‑689 in China. HMPL-689 is a novel, highly selective and potent small molecule inhib

Download Press Release (PDF)

Announcements & Press Releases, Group | 31 Jul 2017

Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs

1 item

London: Monday, July 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the glob

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Jun 2017

Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma

1 item

AstraZeneca PLC (“AstraZeneca”) (LON/STO/NYSE: AZN) Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) London: Thursday, June 29, 2017: Chi-Med and AstraZeneca today announce that they have initiated

Download Announcement (PDF)

Announcements & Press Releases, Group, Press Releases | 29 Jun 2017

Chi-Med to Announce 2017 Half-Year Financial Results

1 item

London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2017 on Monday, July 31, 2017 at 7:00 am British Summer Time (BST). An ana

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 22 Jun 2017

Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China

1 item

Press Release London: Thursday, June 22, 2017: Hutchison China MediTech Limited (“Chi‑Med”) (AIM/Nasdaq: HCM) has just initiated a Phase I/II clinical trial of HMPL‑453 in China. HMPL‑453 is a novel, highly selective and potent small mol

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 12 Jun 2017

Chi-Med Submits New Drug Application to CFDA for Fruquintinib in Advanced Colorectal Cancer

1 item

– Application accepted by CFDA for technical review by the Center for Drug Evaluation – – Triggers RMB30.8 million milestone payment from Eli Lilly and Company (“Lilly”) – London: Monday, June 12, 2017: Hutchison China MediTech L

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 5 Jun 2017

Chi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO

1 item

Press Release Chicago: Monday, June 5, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced that results from its pivotal Phase III trial with fruquintinib, its novel vascular endothelial growth factor receptor (“VEGF

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 18 May 2017

Chi-Med Presents Clinical Data at ASCO 2017 Annual Meeting

1 item

Press Release – FRESCO Phase III trial results for fruquintinib in colorectal cancer in an oral presentation – – Five abstracts in total accepted for fruquintinib, savolitinib and sulfatinib – London: Thursday, May 18, 2017: Hutchison Chin

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 7 Apr 2017

Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017

1 item

London: Friday, April 7, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) presented pre-clinical data for fruquintinib and sulfatinib at the American Association for Cancer Research (“AACR”) Annual Meeting 2017, held in Wa

Download Press Release (PDF)

Announcements & Press Releases, Group | 27 Mar 2017

2016 Annual Report and Notice of Annual General Meeting

1 item

London: Monday, March 27, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2016 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders.

a170327

Announcements & Press Releases, Group, Press Releases | 24 Mar 2017

Chi-Med Appoints Weiguo Su, Chief Scientific Officer, to Board of Directors

1 item

Appointment of Director London: Friday, March 24, 2017: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today announces that Dr Weiguo Su has been appointed as Executive Director and member of Technical Commi

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 21 Mar 2017

Chi-Med to host R&D Briefings on March 29 & 30, 2017

1 item

Press Release London: Tuesday, March 21, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it will host Research & Development (“R&D”) briefings in London and New York to provide an overview o

Download Press Release (PDF)

Announcements & Press Releases, Group, Press Releases | 16 Mar 2017

Grant of Awards under Long Term Incentive Plan

1 item

Press Release London: Thursday, March 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 15, 2017, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive Plan (“LTIP”) a

Download Press Release (PDF)

Announcements & Press Releases, Group | 13 Mar 2017

Publication of Form 20-F for the Year Ended December 31, 2016

1 item

London: Monday, March 13, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2016 per attached and also available for viewing on the Company's website at ww

View Form 20-F (PDF)

Announcements & Press Releases, Group | 13 Mar 2017

Chi-Med Reports Final Results for the Year Ended December 31, 2016 and Updates on Key Clinical Programs

1 item

Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2016 and Updates Shareholders on Key Clinical Programs Group: Record revenue, net income and clinical investment in 2016 Group revenue up 21%

View Full Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 10 Mar 2017

Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of the European Neuroendocrine Tumor Society

1 item

Press Release London: Friday, March 10, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) presented data from the ongoing Phase Ib/II clinical trial of sulfatinib in patients with advanced neuroendocrine tumors (“NET”) at

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology | 3 Mar 2017

Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer

1 item

– Trial met all primary and secondary endpoints – – Safety as expected – – Progressing to China NDA submission mid-2017 – – Full data to be reported at an upcoming scientific meeting in mid-2017 – London: Friday, March 3, 2017: Hu

View Announcement (PDF)

Announcements & Press Releases, Group, Press Releases | 28 Feb 2017

Chi-Med Appoints Graeme Jack as Independent Non-executive Director and Chairman of Audit Committee

1 item

Change of Directors London: Tuesday, February 28, 2017: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today announces that with effect from March 1, 2017:- Mr Graeme Allan Jack has been appointed as I

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 20 Feb 2017

Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma

1 item

Press Release London: Monday, February 20, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that a Phase II study of savolitinib has been initiated in locally advanced or metastatic pulmonary sarcomatoid carci

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 Feb 2017

Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia

1 item

London: Tuesday, February 14, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated the first-in-human (“FIH”) Phase I clinical trial of HMPL-453 in Australia. HMPL-453 is a novel, highly

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 Feb 2017

Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

1 item

Press Release London: Tuesday, February 14, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) and AstraZeneca PLC (“AstraZeneca”) will present data from the ongoing Phase II clinical trial of savolitinib in patients wi

Download Press Release (PDF)

Announcements & Press Releases, Group, Press Releases | 1 Feb 2017

Chi-Med Appoints Industry Veteran Karen Ferrante to Board of Directors

1 item

Change of Directors London: Wednesday, February 1, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that with effect from today:- Dr Karen Jean Ferrante has been appointed as Independent Non-Executive Director

View Announcement (PDF)

Announcements & Press Releases, Group, Press Releases | 16 Jan 2017

Chi-Med Appoints Industry Veteran Paul Carter to Board of Directors

1 item

Change of Directors London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from February 1, 2017, Mr Paul Rutherford Carter has been appointed as Senior Independent Non-Execut

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 16 Jan 2017

Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer

1 item

London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq:HCM) today announces that it has initiated a Phase II study of a combination therapy using fruquintinib and Iressa® in the first-line setting for patients

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 16 Jan 2017

Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China

1 item

London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase II study of sulfatinib in second-line biliary tract cancer (“BTC”) patients in China. Sulfatinib

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 16 Jan 2017

Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017 Gastrointestinal Cancers Symposium

1 item

London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from the ongoing Phase I/II clinical trial of fruquintinib in combination with paclitaxel (Taxol®) in second-line patients

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 10 Jan 2017

Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China

1 item

London: Tuesday, January 10, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase I trial of its novel spleen tyrosine kinase (“Syk”) inhibitor, HMPL-523, in patients with hematolo

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 6 Dec 2016

Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting

1 item

Press Release London: Tuesday, December 6, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from a recent pre-clinical study, investigating the in vitro and in vivo anti-tumor activities of novel Spl

View Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 23 Nov 2016

Chi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”)

1 item

Press Release London: Wednesday, November 23, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that results from two non-small cell lung cancer (“NSCLC”) clinical studies will be presented at WCLC in Vienn

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 Nov 2016

Chi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting

1 item

Press Release London: Monday, November 14, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from a recent Phase I, first-in-human, dose escalating study of the safety, tolerability and pharmacokineti

View Announcement (PDF)

Announcements & Press Releases, Other Ventures, Press Releases | 31 Oct 2016

Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment

1 item

Shanghai agreement triggers a one-time gain to Chi-Med of US$38.2 million in Q4 2016 Shanghai factory relocation complete: now operational with three-fold increase in capacity Cash from Chi-Med Commercial Platform supports developmen

View Announcement (PDF)

Announcements & Press Releases, Group | 2 Aug 2016

Change of Non-executive Directors

1 item

London: Tuesday, August 2, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who ha

View Announcement (PDF)

Announcements & Press Releases, Group | 2 Aug 2016

Chi-Med Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs

1 item

Group revenue up 27% to $104.5 million (H1 2015: $82.5m) and net income attributable to Chi‑Med of $0.5 million (H1 2015: $15.9m), reflecting a sharp increase in clinical investment. Innovation Platform – Seven drug candidates in 25

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 1 Aug 2016

Chi-Med and AstraZeneca Amend Co-development Agreement to Accelerate Savolitinib Global Development Program

1 item

First global pivotal Phase III in c-Met-driven papillary renal cell carcinoma (“PRCC”) to be initiated in the near future London: Monday, August 1, 2016: Chi-Med and AstraZeneca today announced an amendment (the “Amendment”) to the 2011 glo

View Announcement (PDF)

Announcements & Press Releases, Group | 5 Jul 2016

Chi-Med to Announce 2016 Half-Year Financial Results

1 item

London: Tuesday, July 5, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2016 on Tuesday, August 2, 2016 at 7:00 am British Summer Time (BST). An a

View Announcement (PDF)

1 2 3 4 5

7 8 9